Chrystelle Bonnart

Chrystelle Bonnart

Auto-generated profile, based on publicly available information

Chrystelle Bonnart

Affiliation IRSD, Inserm, INRAE, ENVT, University of Toulouse, Toulouse, France

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2022 in British Journal of Pharmacology
Verified
Journal Article
Open access
CDCéline Deraison
Céline Deraison
CBChrystelle Bonnart
Chrystelle Bonnart
PLPhilippe Langella
Philippe Langella
KRKarine Roget
Karine Roget
NVNathalie Vergnolle
Nathalie Vergnolle
Elafin and its precursor trappin‐2 are known for their contribution to the physiological mucosal shield against luminal microbes. Such a contribution seems to be particularly relevant in the gut, where the exposure of host tissues to heavy loads of microbes is constant and contributes to mucosa‐associated pathologies. The expression of trappin‐2/elafin has been shown to be differentially regulated in diseases associated with gut inflammation. Accumulating evidence has demonstrated the protective effects of trappin‐2/elafin in gut intestinal disorders associated with acute or chronic inflammation, or with gluten sensitization disorders. The protective effects of trappin‐2/elafin in the gut are discussed in terms of their pleiotropic modes of action: acting as protease inhibitors, transglutaminase substrates, antimicrobial peptides or as a regulator of pro‐inflammatory transcription factors. Further, the question of the therapeutic potential of trappin‐2/elafin delivery at the intestinal mucosa surface is raised. Whether trappin‐2/elafin mucosal delivery should be considered to ensure intestinal tissue repair is also discussed.

27 September 2017 in Parasite Immunology
Verified
Journal Article
Open access
PDF file
CBC. Bonnart
C. Bonnart
GFG. Feuillet
G. Feuillet
VVV. Vasseur
V. Vasseur
Nicolas CenacNicolas Cenac
Nicolas Cenac
NVN. Vergnolle
N. Vergnolle
NBN. Blanchard
N. Blanchard
Summary: Toxoplasma gondii is a widespread intracellular parasite, which naturally enters the organism via the oral route and crosses the intestinal barrier to disseminate. In addition to neuronal and ocular pathologies, this pathogen also causes gut inflammation in a number of animals. This infection‐triggered inflammation has been extensively studied in the C57BL/6 mice, highlighting the importance of the immune cells and their mediators in the development of gut pathology. However, despite their importance in inflammation, the role of protease‐activated receptors (PAR) was never reported in the context of T.gondii‐mediated small intestine inflammation. Using genetically modified mice, we show that PAR2 plays a pathogenic role in the development of gut inflammatory lesions. We find that PAR2 controls the innate inflammatory mediators IL‐6, KC/CXCL1, PGE2 as well as neutrophil infiltration in T. gondii‐triggered gut damage. These results bring new knowledge on the mechanisms operating in the gut in response to T. gondii infection.

18 April 2024 in British Journal of Pharmacology
Verified
Journal Article
Open access
SGSimon Guignard
Simon Guignard
MSMahmoud Saifeddine
Mahmoud Saifeddine
KMKoichiro Mihara
Koichiro Mihara
MMMajid Motahhary
Majid Motahhary
MSMagali Savignac
Magali Savignac
CBChrystelle Bonnart
Chrystelle Bonnart
Background and Purpose: Chymotrypsin is a pancreatic protease secreted into the lumen of the small intestine to digest food proteins. We hypothesized that chymotrypsin activity may be found close to epithelial cells and that chymotrypsin signals to them via protease‐activated receptors (PARs). We deciphered molecular pharmacological mechanisms and gene expression regulation for chymotrypsin signalling in intestinal epithelial cells.Experimental Approach: The presence and activity of chymotrypsin were evaluated by Western blot and enzymatic activity tests in the luminal and mucosal compartments of murine and human gut samples. The ability of chymotrypsin to cleave the extracellular domain of PAR1 or PAR2 was assessed using cell lines expressing N‐terminally tagged receptors. The cleavage site of chymotrypsin on PAR1 and PAR2 was determined by HPLC–MS analysis. The chymotrypsin signalling mechanism was investigated in CMT93 intestinal epithelial cells by calcium mobilization assays and Western blot analyses of (ERK1/2) phosphorylation. The transcriptional consequences of chymotrypsin signalling were analysed on colonic organoids.Key Results: We found that chymotrypsin was present and active in the vicinity of the colonic epithelium. Molecular pharmacological studies have shown that chymotrypsin cleaves both PAR1 and PAR2 receptors. Chymotrypsin activated calcium and ERK1/2 signalling pathways through PAR2, and this pathway promoted interleukin‐10 (IL‐10) up‐regulation in colonic organoids. In contrast, chymotrypsin disarmed PAR1, preventing further activation by its canonical agonist, thrombin.Conclusion and Implications: Our results highlight the ability of chymotrypsin to signal to intestinal epithelial cells via PARs, which may have important physiological consequences in gut homeostasis.

15 May 2005 in médecine/sciences
Verified
Journal Article
Open access
PDF file
PDPascal Descargues
Pascal Descargues
CDCéline Deraison
Céline Deraison
CBChrystelle Bonnart
Chrystelle Bonnart
AHAlain HOVNANIAN
Alain HOVNANIAN

29 April 2025 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
AAAlexis Audibert
Alexis Audibert
XMXavier Mas-Orea
Xavier Mas-Orea
LRLéa Rey
Léa Rey
MBMarcy Belloy
Marcy Belloy
EBEmilie Bassot
Emilie Bassot
NBNicolas Blanchard
Nicolas Blanchard
By eliciting immune activation in the digestive tract, intestinal pathogens may perturb gut homeostasis. Some gastrointestinal infections can indeed increase the risk of developing post-infectious irritable bowel syndrome (PI-IBS). Intriguingly, the prevalent foodborne parasite Toxoplasma gondii has not been linked to the development of PI-IBS and the impact of this infection on colon homeostasis remains ill-defined. We show in a mouse model that latent T. gondii decreases visceral nociceptive responses in an opioid signaling-dependent manner. Despite the accumulation of Th1 and cytotoxic T cells in the colon of latently infected mice, the selective invalidation of enkephalin gene in T cells ruled out the involvement of T cell-derived enkephalins in hypoalgesia. These findings provide clues about how this widespread infection durably shapes the gut immune landscape and modifies intestinal physiological parameters. They suggest that in contrast to other gut microbes, T. gondii infection could be negatively associated with abdominal pain.

26 January 2017 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
NTN. Solà Tapias
N. Solà Tapias
ADA. Denadai-Souza
A. Denadai-Souza
CRC. Rolland-Fourcade
C. Rolland-Fourcade
CBC. Blanpied
C. Blanpied
GDG. Dietrich
G. Dietrich
FBF. Barreau
F. Barreau
Background: Studies on ulcerative colitis (UC) patients show an excessive induction of endoplasmic reticulum stress (ERS) in intestinal epithelial cells (IEC) of the colonic mucosa, leading to intestinal barrier disruption and inflammation. Moreover, the secretion of serine proteases from IEC is enhanced in UC patients. Herein, we hypothesized that intestinal barrier (IB) disruption and mucosal inflammation associated to ERS in UC are mediated by an increased release of serine proteases. Therefore, we aimed to study the link between ERS and proteolytic activity and its impact on IB functions Methods: Monoloayers of differentiated Caco-2 cells grown in a transwell system were stimulated with thapsigargin or tunicamycin to induce ERS. After 6 and 24 hours, supernatants were collected to quantify trypsin-like activity. Paracellular permeability to dextran-FITC, ELISA to IL-8 and gene expression of antimicrobial peptides (AMC) were assessed to evaluate the impact of proteases on IB, by treating cells with the irreversible serine protease inhibitor (AEBSF). Moreover, antagonists of protease-activated receptors (PAR-1, -2 and -4) were used to characterize the mechanism of action. Results: ERS activation increased trypsin-like activity in supernatants from the apical side of Caco-2 monolayers, at 6 hours, while this effect is lost at 24 hours, probably due to store depletion. After ERS induction, we observed increased paracellular permeability, enhanced IL-8 release and upregulated AMP (DEFB1 (HBD1), DEFB4 (HBD2), MUC2, MUC5 and TTF3). In contrast, AEBSF recovered paracellular permeability, diminished IL-8 release, and at 24h, AMP mRNA levels were stabilized in ERS-induced cells. F2LR1 (PAR-2) and F2LR3 (PAR4s) mRNA levels increased after ERS induction. Furthermore, the increase of paracellular permeability associated to ERS activation was reduced 24h after treatment with PARs antagonists. Conclusions: IEC under ERS increases TLA, which in turn disturbs IB by promoting paracellular permeability, chemokine induction and deregulation of AMP expression. Besides, the disturbance of IB and inflammation seems to be mediated by PAR activation. In conclusion, our data suggest a crosstalk between ERS and proteolytic activity, two fundamental features of UC.